Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7405389 | 0.78 | CA1 (0.44) | ALDH1A1L3MBTL1NPC1RAB9AHPGD | |
| SCHEMBL27568084 | 0.75 | ELANE (0.53) | ELANEALDH1A1L3MBTL1HPGDMAPT | |
| SCHEMBL1590016 | 0.74 | ELANE (1.00) | ELANEALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL3147633 | 0.74 | ALDH1A1 (0.58) | ELANEALDH1A1SRD5A2L3MBTL1NPC1 | |
| SCHEMBL6198568 | 0.73 | LMNA (0.50) | ELANEALDH1A1MEN1KMT2AMAPT | |
| Benzophenone SCHEMBL28134565 | 0.72 | ALDH1A1 (0.67) | ELANEALDH1A1SRD5A2L3MBTL1NPC1 | |
| SCHEMBL7723363 | 0.72 | ABCB11 (0.44) | ELANEALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9709124 | 0.72 | ALDH1A1 (0.54) | ELANEALDH1A1SRD5A2L3MBTL1NPC1 | |
| Benzophenone SCHEMBL6392094 | 0.71 | ALDH1A1 (0.82) | ELANEALDH1A1SRD5A2L3MBTL1NPC1 | |
| Benzophenone SCHEMBL28512056 | 0.71 | ALDH1A1 (0.82) | ELANEALDH1A1SRD5A2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | claimed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | claimed |
| JP-4267922-B2 | — | — | 2009-05-27 | — | — | JP | claimed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | claimed |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | claimed |
| US-7026510-B2 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | Dompé S.p.A. (IT) | 2006-04-11 | — | — | US | claimed |
| CN-1732145-A | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE SPA (IT) | 2006-02-08 | — | — | CN | claimed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | claimed |
| US-6887903-B1 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. (IT) | 2005-05-03 | — | — | US | claimed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | claimed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | claimed |
| EP-1430020-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-06-23 | — | — | EP | claimed |
| EP-1366018-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.P.A. (IT) | 2003-12-03 | — | — | EP | claimed |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. | 2003-11-20 | — | — | US | claimed |
| WO-2003029187-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-04-10 | — | — | WO | claimed |
| EP-1123276-B1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE SPA (IT) | 2003-01-08 | — | — | EP | claimed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | claimed |
| WO-2002068377-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.p.A. (IT) | 2002-09-06 | — | — | WO | claimed |
| CN-1324344-A | N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2001-11-28 | — | — | CN | claimed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | ELANE, MPO, FPR1 | ELANE 1/4885ALDH1A1 552/4885SRD5A2 1519/4885 |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | ELANE 219/4885ALDH1A1 689/4885SRD5A2 1117/4885 |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | ELANE 219/4885ALDH1A1 494/4885SRD5A2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.